Flucelvax Trivalent 2024-2025 is an injectable vaccine that protects against three strains of the influenza virus. It is approved for use in people 6 months of age and older.
Flucelvax Trivalent 2024-2025 is made using a cell culture-based production method. This means that the vaccine is produced in a controlled environment using mammalian cells. This method is more efficient and less expensive than traditional egg-based production methods.
Flucelvax Trivalent 2024-2025 has been shown to be safe and effective in clinical trials. It is well-tolerated, with the most common side effects being injection site pain, redness, and swelling.
